News About: Pharm. Affairs
KPDS, “Conditionally-approved Tasigna’s clinical trial result must be disclosed”
Korean Pharmacists for Democratic Society(KPDS) announced to make a request for disclosure of the clinical trial result of Novartis’ ‘Tasigna.’
Novartis acquired conditional approval for the Phase 3 clinical trial of...
New KPMA Chairman’s Quick movements
While its chairmen, executives and employees attended the inauguration of the 21st Korea Pharmaceutical Manufacturers Association(KPMA) Chairman on the last 2nd, Hee-Mok Won, the new chairman who started the 2-year te...
What are reasons why there have been a drought in new drug approval?
It seems it would be hard new drug developed by Korean pharmaceutical company to be commercialized this year, again.
The Ministry of Food and Drug Safety anticipated 1 Korean new drug will acquire approval this year....
Chairman Hee-Mok Won, “It’s is important to harmonize industrial and public values”
Hee-Mok Won, a former member of the National Assembly, was appointed as the 21st Chairman of the Korea Pharmaceutical Manufacturers Association(KPMA).
The KPMA had the inauguration ceremony of Chairman Hee-Mok Won wi...
Korean pharma market encroached by overseas companies with imports increased by 19%
Last year, imports of pharmaceutical and cosmetic products were increased by 13.6% compared to the year before.
Particularly, imports of finished drugs were enlarged by 19%, which shows the multinational pharmaceutic...
154 products approved on February, 42 of them(27%) were OTC
Last February, there were 154 pharmaceutical products approved, and 42 of them(27%) were a OTC drug.
According to the Ministry of Food and Drug Safety(MFDS), 80 companies newly acquired approval for 154 pharmaceutica...
Will water-leaking Korean Pharmaceutical Association Bldg. be discussed for reconstruction?
The issue of reconstructing Korean Pharmaceutical Association Bldg. has been raised again. The industry has shown interests if the issue will be voted by the members in favor of the reconstruction.
The members have a...
Kyowa Kakko Kirin signs license agreement of hyperphosphatemia treatment ‘Nephoxil’
Kyowa Hakko Kirin Korea(CEO Shigeaki Suzuki) announced a license agreement of the hyperphosphatemia treatment ‘Nephoxil’ with Taiwanese Panion & BF Biotech on the 20th of February.
Hyperphosphatemia is a symptom in w...
Implementation of 3-year license reporting system for doctors and Korean medicine doctors
The 3-year license reporting system for doctors and Korean medicine doctors will be implemented, and if they do not renew their license, the license will be suspended.
On the 16th, the Ministry of Health and Welfare ...
“Despite side effects of Tamifly, health authorities have no follow-up actions at all”
While flu patients have recently occurred for the highest number in the history, the side effect issue of Tamiflu, the bird flu treatment, is getting severe.
According to the number of Tamiflu’s side effect reports s...
